surmount-2 tirzepatide type 2 diabetes weight loss results 2023 2024 for Obesity Treatment and Prevention Frontiers | Tirzepatide's innovative applications

Weight loss and liver enzymes Participants on semaglutide lost an average of 10.5% of their body weight, compared to 2% on placebo

If Foundayo's clinical outcomes hold up in real-world use (the Phase 3 ATTAIN-1 trial showed 11.2% mean weight loss at 72 weeks on the 36 mg dose, or 12.4% among participants who stayed on treatment), it could become the go-to affordable GLP-1 option and put downward pressure on Wegovy and Zepbound pricing

Understanding how these medications work is essential context for exploring their potential effects on reproductive health and fertility

It could improve your autoimmune response and reduce inflammation

Learn how it works, how to get it, and whether it's right for you.

To make an informed choice, you need to look past the marketing and focus on the formulation quality